A Phase 1, Open-Label, Dose-Finding Study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of A SARS-COV-2 RNA Vaccine Candidate Against Covid-19 in Heal

Sub-indication: COVID-19

Drug Study

Principal Investigator: Gary Marshall, M.D.
Norton Children's Infectious Diseases, affiliated with the UofL School of Medicine

Sponsor: Pfizer

Search our entire site.